Akums launches Lasmiditan tablet to confront migraine challenges

Lasmiditan high central nervous system penetration ensures a more targeted approach to migraine management 

In a step towards addressing the persistent challenge of migraine, Akums Drugs & Pharmaceuticals, a contract manufacturing pharmaceutical company, has launched the Lasmiditan tablet. This medication has received approvals from the Drug Controller General of India (DCGI) and the United States Food and Drug Administration (USFDA).

Migraine, a chronic neurovascular disorder affecting millions globally, is characterised by recurrent, severe headaches accompanied by nausea and sensitivity to light and sound.

In a 2019 report, it was revealed that headache disorders, including both migraines and tension-type headaches, have emerged as the most prevalent neurological conditions in India, affecting an astonishing 488 million individuals.

The International Headache Society (IHS) outlines criteria for diagnosing migraine, including specific characteristics and associated symptoms observed in at least five attacks. Two main subtypes, migraine without aura and migraine with aura, present distinct features, with the latter involving focal neurological symptoms preceding or accompanying the headache.

Lasmiditan belongs to the “selective serotonin receptor agonists” class of medications and is specifically designed to alleviate the symptoms associated with migraine headaches. The medication is formulated to interrupt pain signals to the brain and address nerve inflammation contributing to migraine symptoms. Each film-coated tablet of Lasmiditan contains lasmiditan hemisuccinate 57.824 mg/115.65 mg eq. to Lasmiditan 50mg/100mg. By binding with the 5-HT1F receptor, Lasmiditan presents an avenue for migraine relief.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!